• IDEAYA Biosciences presented complete primary-analysis data at ASCO 2026 from its registrational OptimUM-02 trial in first-line metastatic uveal melanoma.
• The darovasertib-crizotinib combination outperformed investigator’s choice therapy on disease control outcomes, supporting a potential new standard for HLA-A2:01 negative patients.
• Overall survival results were not yet mature, though early data favored the combination; the next update is planned at a pre-specified interim analysis.
• Safety was described as manageable, with fewer treatment-related serious events and fewer discontinuations than the control arm.
• An NDA submission is in process under FDA’s RTOR program, with filing expected to be completed in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606011100PR_NEWS_USPR_____SF71955) on June 01, 2026, and is solely responsible for the information contained therein.